Blacksburg S et al. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases. Curr Treat Options Oncol 2015;16(3):325. Abstract

Dorff TB et al. Radium 223: How can we optimize this new tool for metastatic castration-resistant prostate cancer? Am Soc Clin Oncol Educ Book 2015;35:e270-3. Abstract

Finkelstein SE et al. External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial. Genitourinary Cancers Symposium 2015;Abstract 182.

Park JC et al. Randomized phase-2 study of sipuleucel-T with or without radium-223 in men with asymptomatic/minimally symptomatic bone-metastatic castrate-resistant prostate cancer (CRPC). Proc ASCO 2015;Abstract TPS076.

Petrylak DP et al. A randomized open-label phase 2a study evaluating the efficacy and safety of radium-223 dichloride (Ra-223) in combination with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC) and bone metastases. Proc ASCO 2014;Abstract TPS5103.

Smith RS et al. ERA 223: A phase 3 trial of radium-223 dichloride (Ra-223) in combination with abiraterone acetate (abiraterone) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone predominant metastatic castration-resistant prostate cancer (mCRPC). Proc ASCO 2015;Abstract TPS5082.